Back to top
more

ViewRay, Inc. (VRAY)

(Delayed Data from NSDQ)

$4.15 USD

4.15
3,126,069

-0.10 (-2.35%)

Updated Mar 4, 2021 04:00 PM ET

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.41%
2Buy17.88%
3Hold9.48%
4Sell5.03%
5Strong Sell1.87%
S&P50010.70%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth C Momentum F VGM

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 28% (184 out of 254)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Trades from $1

Zacks News

ViewRay (VRAY) Reports Q4 Loss, Tops Revenue Estimates

ViewRay (VRAY) delivered earnings and revenue surprises of -5.88% and 2.52%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

ViewRay (VRAY) Reports Q3 Loss, Tops Revenue Estimates

ViewRay (VRAY) delivered earnings and revenue surprises of -11.76% and 13.15%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Will ViewRay (VRAY) Report Negative Earnings Next Week? What You Should Know

ViewRay (VRAY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ViewRay (VRAY) Catches Eye: Stock Jumps 7%

ViewRay (VRAY) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

ViewRay (VRAY) Reports Q2 Loss, Tops Revenue Estimates

ViewRay (VRAY) delivered earnings and revenue surprises of -12.50% and 144.95%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

PerkinElmer (PKI) Q2 Earnings and Revenues Surpass Estimates

PerkinElmer's (PKI) second-quarter results benefit from growth in Diagnostics segment. However, forex remains a woe.

DexCom (DXCM) Q2 Earnings and Revenues Surpass Estimates

DexCom's (DXCM) second-quarter results benefit from solid segmental performance.

Masimo (MASI) Earnings and Revenues Beat Estimates in Q2

Masimo (MASI) continues to gain from key Product segment, which witnessed solid growth in Q2.

LabCorp (LH) Beats Q2 Earnings Estimates, Margins Decline

LabCorp (LH) witnesses a 20.7% decline in organic volume, partially offset by acquisition volume growth of 1.2%.

Ecolab (ECL) Earnings and Revenues Lag Estimates in Q2

Ecolab's (ECL) second-quarter results reflect weakness in the Global Industrial and Institutional segments.

Edwards Lifesciences (EW) Beats on Q2 Earnings, Ups EPS View

Despite coronavirus-hit sales, Edwards Lifesciences (EW) witnessed steady improvement in TAVR procedure volumes in Q2. Regulatory approvals look encouraging.

Will ViewRay (VRAY) Report Negative Earnings Next Week? What You Should Know

ViewRay (VRAY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Quest Diagnostics' (DGX) Q2 Earnings Beat, Volume Declines

Following the guidance withdrawal last quarter, Quest Diagnostics (DGX) provides its full-year projection alongside Q2 earnings release.

Align Technology (ALGN) Earnings Fall Shy of Estimates in Q2

Align Technology's (ALGN) segments report COVID-19-led lower sales across major geographies.

ViewRay (VRAY) to Report Q2 Earnings: What's in the Offing?

Strength in MRIdian system business is likely to have aided ViewRay's (VRAY) performance in second-quarter 2020 amid the coronavirus-led economic doldrums.

Neogen (NEOG) Q4 Earnings Beat Estimates, Margins Expand

Neogen's (NEOG) Animal Safety revenues improve in the fourth quarter on strong sales of cleaners, disinfectants and sanitizers.

Thermo Fisher (TMO) Q2 Earnings Beat on COVID-19-Led Sales

We are encouraged about Thermo Fisher's (TMO) exceptionally strong year-over-year revenue growth at Life Sciences Solutions segment.

Intuitive Surgical (ISRG) Q2 Earnings Top Estimates, Down Y/Y

Intuitive Surgical's (ISRG) second-quarter results reflect weak performance across all businesses and lower revenues.

Neuronetics (STIM) Looks Good: Stock Adds 11.3% in Session

Neuronetics (STIM) saw a big move last session, as its shares jumped more than 11% on the day, amid huge volumes.

AngioDyanamics (ANGO) Reports Q4 Loss, Revenues Lag Estimates

AngioDyanamics (ANGO) witnessed revenue decline across all business segments in Q4.

Abbott (ABT) Q2 Earnings Top, Coronavirus Test Sales Solid

Abbott (ABT) Q2 earnings reflect healthy growth within its Diabetes Care business and encouraging coronavirus test sales.

Urmimala Biswas headshot

Medical Instruments Outlook Dull Amid Coronavirus Crisis

Many sub domains within the medical instrument space are bearing the brunt of the coronavirus-led prolonged stay-at-home orders.

The Zacks Analyst Blog Highlights: Domo, ViewRay, Commercial Metals, Clearwater Paper and Momenta Pharmaceuticals

The Zacks Analyst Blog Highlights: Domo, ViewRay, Commercial Metals, Clearwater Paper and Momenta Pharmaceuticals

Nalak Das headshot

5 Top Momentum Stocks of June Amid Resurgence of Coronavirus

Despite market's roller-coaster ride, a handful of momentum stocks with a favorable Zacks Rank have provided double-digit returns so far in June.

Top Ranked Momentum Stocks to Buy for June 23rd

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, June 23rd